Cg Oncology Inc (CGON)

$26.31 -0.38 (-1.42%)
Market Cap 2.01B
Revenue (ttm) 1.14M
Net Income (ttm) -88.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,722.81%
Debt to Equity Ratio 0.00
Volume 815,500
Avg Vol 899,808
Day's Range N/A - N/A
Shares Out 76.23M
Stochastic %K 45%
Beta 0.87
Analysts Strong Sell
Price Target $56.80

Company Profile

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC p...

Industry: Biotechnology
Sector: Healthcare
Phone: 949 409 3700
Address:
400 Spectrum Center Drive, Suite 2040, Irvine, United States
monterocky848
monterocky848 Jul. 31 at 11:53 PM
$ANIP $CGON Hey win a lawsuit that guarantees no one is touching your revenue and fucking down; Why not
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 30 at 11:46 AM
$CGON (+5.6% pre) CG Oncology wins Delaware jury trial against ANI Pharmaceuticals $ANIP https://ooc.bz/l/71754
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 29 at 6:00 PM
$CGON Really good write-up that perfectly summarizes CGON's present situation. So if you want to bring your CGON knowledge up to date or just discover CGON, this is required reading. https://beyondspx.com/article/cg-oncology-unpacking-the-bladder-cancer-catalyst-cgon
0 · Reply
pat_soons_shlong
pat_soons_shlong Jul. 24 at 6:02 AM
$CGON seriously thinking of entering a position here. I remember when this was an IPO Someone want to give me the numbers on the recent dilution and the reason for the April dump? Any timeline on FDA BLA approval? Or just 2H
1 · Reply
stonktrader99
stonktrader99 Jul. 22 at 7:54 PM
$CGON @monterocky848 Hold strong brother, gains otw.
0 · Reply
monterocky848
monterocky848 Jul. 22 at 4:58 PM
$CGON the only fucking biospec that establishes a lower base each milestone
0 · Reply
monterocky848
monterocky848 Jul. 22 at 4:50 PM
$CGON trash fucking stock; submit ur fucking BLA so I can exit please
0 · Reply
monterocky848
monterocky848 Jul. 22 at 4:31 PM
$CGON solid week there COGI
0 · Reply
stockanalysis_
stockanalysis_ Jul. 22 at 12:34 PM
Premarket Losers: $REPL $AIRE $ORIS $TNFA $CGON View the entire list here: https://stockanalysis.com/markets/premarket/losers/?ref=saveontrading
0 · Reply
monterocky848
monterocky848 Jul. 15 at 9:25 PM
$CGON what a fucking surprise at the low again just like every other fucking day
0 · Reply
Latest News on CGON
CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)

Jun 23, 2025, 9:58 AM EDT - 5 weeks ago

CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 8:00 AM EDT - 2 months ago

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

May 13, 2025, 8:00 AM EDT - 2 months ago

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

Apr 28, 2025, 11:14 AM EDT - 3 months ago

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

Apr 26, 2025, 4:10 PM EDT - 3 months ago

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

CG Oncology Looks Attractive At Current Prices (Rating Upgrade)

Apr 2, 2025, 12:32 PM EDT - 4 months ago

CG Oncology Looks Attractive At Current Prices (Rating Upgrade)

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

Mar 24, 2025, 8:00 AM EDT - 4 months ago

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 5 months ago

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 16, 2024, 4:05 PM EST - 8 months ago

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

Dec 13, 2024, 2:09 PM EST - 8 months ago

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

CG Oncology Announces Pricing of Public Offering

Dec 12, 2024, 8:19 PM EST - 8 months ago

CG Oncology Announces Pricing of Public Offering

CG Oncology Announces Proposed Public Offering

Dec 11, 2024, 6:17 AM EST - 8 months ago

CG Oncology Announces Proposed Public Offering

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

Dec 6, 2024, 1:18 PM EST - 8 months ago

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Dec 6, 2024, 8:00 AM EST - 8 months ago

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Dec 5, 2024, 7:00 AM EST - 8 months ago

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 30, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

CG Oncology: Promising Data, But Looks Expensive

Aug 26, 2024, 10:34 AM EDT - 1 year ago

CG Oncology: Promising Data, But Looks Expensive

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 8, 2024, 8:23 AM EDT - 1 year ago

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

Jul 9, 2024, 9:19 AM EDT - 1 year ago

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

Jun 6, 2024, 12:14 PM EDT - 1 year ago

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

May 24, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

May 9, 2024, 8:00 AM EDT - 1 year ago

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

May 6, 2024, 1:04 PM EDT - 1 year ago

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

May 3, 2024, 11:23 AM EDT - 1 year ago

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

Apr 26, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

Apr 24, 2024, 10:00 AM EDT - 1 year ago

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Mar 28, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Protara: A Bombed Out Biotech With A Very Positive Skew

Feb 22, 2024, 8:55 AM EST - 1 year ago

Protara: A Bombed Out Biotech With A Very Positive Skew

TARA

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 30, 2024, 7:00 AM EST - 1 year ago

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues

Jan 29, 2024, 8:14 AM EST - 1 year ago

American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues

BTSG

U.S. IPO Weekly Recap: Biotech CG Oncology Pops 96% In A 7 IPO Week

Jan 27, 2024, 1:30 AM EST - 1 year ago

U.S. IPO Weekly Recap: Biotech CG Oncology Pops 96% In A 7 IPO Week

Biotech's First IPO of 2024 Popped 96%. What It Means.

Jan 26, 2024, 11:50 AM EST - 1 year ago

Biotech's First IPO of 2024 Popped 96%. What It Means.

CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality

Jan 25, 2024, 2:20 PM EST - 1 year ago

CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality

CG Oncology valued at $1.75 bln in strong market debut

Jan 25, 2024, 1:46 PM EST - 1 year ago

CG Oncology valued at $1.75 bln in strong market debut

CG Oncology IPO prices above range and boosts share count in bullish move ahead of trading

Jan 25, 2024, 7:51 AM EST - 1 year ago

CG Oncology IPO prices above range and boosts share count in bullish move ahead of trading

CG Oncology Announces Pricing of Upsized Initial Public Offering

Jan 24, 2024, 7:10 PM EST - 1 year ago

CG Oncology Announces Pricing of Upsized Initial Public Offering

monterocky848
monterocky848 Jul. 31 at 11:53 PM
$ANIP $CGON Hey win a lawsuit that guarantees no one is touching your revenue and fucking down; Why not
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 30 at 11:46 AM
$CGON (+5.6% pre) CG Oncology wins Delaware jury trial against ANI Pharmaceuticals $ANIP https://ooc.bz/l/71754
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 29 at 6:00 PM
$CGON Really good write-up that perfectly summarizes CGON's present situation. So if you want to bring your CGON knowledge up to date or just discover CGON, this is required reading. https://beyondspx.com/article/cg-oncology-unpacking-the-bladder-cancer-catalyst-cgon
0 · Reply
pat_soons_shlong
pat_soons_shlong Jul. 24 at 6:02 AM
$CGON seriously thinking of entering a position here. I remember when this was an IPO Someone want to give me the numbers on the recent dilution and the reason for the April dump? Any timeline on FDA BLA approval? Or just 2H
1 · Reply
stonktrader99
stonktrader99 Jul. 22 at 7:54 PM
$CGON @monterocky848 Hold strong brother, gains otw.
0 · Reply
monterocky848
monterocky848 Jul. 22 at 4:58 PM
$CGON the only fucking biospec that establishes a lower base each milestone
0 · Reply
monterocky848
monterocky848 Jul. 22 at 4:50 PM
$CGON trash fucking stock; submit ur fucking BLA so I can exit please
0 · Reply
monterocky848
monterocky848 Jul. 22 at 4:31 PM
$CGON solid week there COGI
0 · Reply
stockanalysis_
stockanalysis_ Jul. 22 at 12:34 PM
Premarket Losers: $REPL $AIRE $ORIS $TNFA $CGON View the entire list here: https://stockanalysis.com/markets/premarket/losers/?ref=saveontrading
0 · Reply
monterocky848
monterocky848 Jul. 15 at 9:25 PM
$CGON what a fucking surprise at the low again just like every other fucking day
0 · Reply
Dy2ski
Dy2ski Jul. 11 at 11:05 PM
$CGON CFO is out. Interesting timing with $ANIP Patent Lawsuit against CGON set to begin soon this month...and $CGON also, conveniently waited to dump the CFO *quitting* news 4 days later on a Friday. Hmmmm.
1 · Reply
monterocky848
monterocky848 Jul. 11 at 7:40 PM
$CGON end at the low like u do every fucking day
0 · Reply
monterocky848
monterocky848 Jul. 11 at 7:15 PM
$CGON giant fucking waste of time and capital; when it does say something once a year the pop lasts for 30 seconds; get ready for the 30 second BLA pop if it ever fucking comes then short
0 · Reply
monterocky848
monterocky848 Jul. 11 at 2:38 PM
$CGON shocking another jack shit week; make that 3 years
0 · Reply
KNel
KNel Jul. 9 at 4:31 PM
$CGON Do I smell BLA in the near future? Let this baby keep climbing!
1 · Reply
monterocky848
monterocky848 Jul. 7 at 6:31 PM
$CGON $CLDI $MRK $REGN $RHHBY who fucking cares
0 · Reply
NetworkNewsWire
NetworkNewsWire Jul. 7 at 1:07 PM
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs $CLDI $REGN $CGON $RHHBY $MRK https://ibn.fm/fSEy9
0 · Reply
monterocky848
monterocky848 Jul. 2 at 8:26 PM
$CGON amazing how this stock drops .50 on cue at 340 everyday on 2 trades
0 · Reply
monterocky848
monterocky848 Jun. 27 at 5:52 PM
$CGON shocking another week of jack shit except fade
1 · Reply
BigBill187
BigBill187 Jun. 25 at 1:34 AM
$CGON how long after phase 3 ends is typical approval 6 months plus??
0 · Reply
JayBiotech1
JayBiotech1 Jun. 23 at 1:38 PM
$CGON looks like it may trade back down into low 20's
1 · Reply
swingingtech
swingingtech Jun. 21 at 12:39 AM
$IGT $CGON $GME https://wallstreetwaves.com/significant-friday-options-trading-igt-cgon-gme/
0 · Reply